References
- SorianoJBLamprechtBChronic obstructive pulmonary disease: a worldwide problemMed Clin North Am201296467168022793937
- FangXWangXBaiCCOPD in China: The burden and importance of proper managementChest2011139492092921467059
- Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]Global Strategy for the Diagnosis, Management and Prevention of COPD2014 Available from: http://www.goldcopd.org/Accessed April 8, 2014
- D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
- KerwinEHebertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
- D’UrzoAKerwinEOverendTD’AndreaPChenHGoyalPOnce daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studiesCur Med Res Opin2014303493508
- ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulmon Med2014144
- BeehKMSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J COPD20127503513
- KirkpatrickdPDransfieldMTRacial and sex differences in chronic obstructive pulmonary disease susceptibility, diagnosis, and treatmentCurr Opin Pulmon Med2009152100104
- MartinABadrickEMathurRHullSEffect of ethnicity on the prevalence, severity, and management of COPD in general practiceBrit J Gen Pract201262595e76e8122520773
- YasudaSUZhangLHuangSMThe role of ethnicity in variability in response to drugs: focus on clinical pharmacology studiesClin Pharmacol Ther200884341742318615002
- JonesROstremAOptimising pharmacological maintenance treatment for COPD in primary carePrim Care Respir J2011201334521103801
- RocheNSmallMBroomfieldSHigginsVPollardRReal World COPD: Association of Morning Symptoms with Clinical and Patient Reported OutcomesCOPD201310667968624127914
- WestwoodMBourbeauJJonesPWCerulliACapkun-NiggliGWorthyGRelationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic reviewRespir Res2011124021477298
- AnzuetoAImpact of exacerbations on COPDEur Respir Rev20101911611311820956179
- DonohueJFFogartyCLotvallJOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
- JonesPWRennardSIAgustiAEfficacy and safety of once-daily aclidinium in chronic obstructive pulmonary diseaseRespir Res2011125521518460
- MatthysHPliskevichDABondarchukOMMalekFATribanekMKieserMRandomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPDRespir Med2013107569170123478193
- DrollmanASechaudRPalPHaraHUziel-FusiSWinklePGlycopyrronium does not affect QT interval in healthy subjects: a randomized, three-period, cross-over, placebo- and positive-controlled studyInt J Clin Pharmacol Ther201452973974524986094